Back to Report Store Home

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics

  • Published: Jun-2016
  • Report Code: GBIHC412MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Urologic Oncology, Major Markets, Treatment Usage Patterns for Bladder Cancer, Patients (’000), 2015-2022 15

Figure 2: Urologic Oncology, Major Markets, Treatment Usage Patterns for Kidney Cancer, Patients (’000), 2015–2022 16

Figure 3: Urologic Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (’000), 2015-2022 17

Figure 4: Urologic Oncology, Major Markets, Treatment Usage Patterns for Testicular Cancer, Patients (’000), 2015–2022 18

Figure 5: Urological Cancer, Global, Key Marketed Products and Approved Indications, 2015 25

Figure 6: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Zytiga ($bn), 2011–2022 27

Figure 7: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xtandi ($bn), 2012–2022 28

Figure 8: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Sutent ($bn), 2006–2022 29

Figure 9: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Votrient ($bn), 2010–2022 30

Figure 10: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Inlyta ($m), 2012–2022 31

Figure 11: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Jevtana ($m), 2012–2022 33

Figure 12: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xofigo ($bn), 2013–2022 34

Figure 13: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Provenge ($m), 2010–2022 35

Figure 14: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Opdivo ($bn), 2015–2022 36

Figure 15: Urologic Oncology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 38

Figure 16: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2016 40

Figure 17: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016 41

Figure 18: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016 42

Figure 19: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Molecular Target, 2016 44

Figure 20: Urologic Oncology Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 45

Figure 21: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016 46

Figure 22: Urologic Oncology Therapeutics Market, Global, Urologic Clinical Trial by Indication (%), 2006–2016 47

Figure 23: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 48

Figure 24: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 49

Figure 25: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 50

Figure 26: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 51

Figure 27: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (months), 2006–2016 52

Figure 28: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 53

Figure 29: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 54

Figure 30: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 55

Figure 31: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2016 56

Figure 32: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 57

Figure 33: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 58

Figure 34: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 59

Figure 35: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2016 60

Figure 36: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 61

Figure 37: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 62

Figure 38: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 63

Figure 39: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for atezolizumab ($bn), 2016–2022 65

Figure 40: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab ($bn), 2017–2022 66

Figure 41: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab + Tremelimumab ($m), 2018–2022 67

Figure 42: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Apalutamide ($m), 2018–2022 68

Figure 43: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Avelumab ($m), 2016–2022 69

Figure 44: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Tivozanib ($m), 2016–2022 70

Figure 45: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Eoquin ($m), 2017–2022 71

Figure 46: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Prostvac ($m), 2016–2022 72

Figure 47: Urologic Oncology, Global, Market Size ($bn), 2015–2022 74

Figure 48: Urologic Oncology, Global, Market Size ($bn), 2015–2022 75

Figure 49: Urologic Oncology, Global, Annual Revenue Forecast for Key Products ($bn), 2015–2022 76

Figure 50: Urologic Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2015–2022 78

Figure 51: Urologic Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1 Inhibitor ($bn), 2015–2022 79

Figure 52: Urologic Oncology, Global, Annual Revenue Forecast for VEGF Inhibitors ($bn), 2015–2022 80

Figure 53: Urologic Oncology, Global, Annual Revenue Forecast for GNRH Inhibitors ($m), 2015–2022 81

Figure 54: Urologic Oncology, Global, Annual Revenue Forecast for Tubulin Inhibitors ($m), 2015–2022 82

Figure 55: Urologic Oncology, Global, Annual Revenue Forecast for CTLA-4 ($m), 2017–2022 82

Figure 56: Urologic Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2015–2022 83

Figure 57: Urologic Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2015–2022 85

Figure 58: Urologic Oncology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 86

Figure 59: Urologic Oncology, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 87

Figure 60: Urologic Oncology, Global, Revenues by Product Type, 2015–2022 88

Figure 61: Urologic Oncology, Global, Pfizer Urologic Oncology Annual Revenue Forecast ($bn), 2015–2022 89

Figure 62: Urologic Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2015–2022 90

Figure 63: Urologic Oncology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015–2022 91

Figure 64: Urologic Oncology, Global, Astellas Pharma Inc. Annual Revenue Forecast ($bn), 2015–2022 92

Figure 65: Urologic Oncology, AstraZeneca Plc. Annual Revenue Forecast ($bn), 2015–2022 93

Figure 66: Urologic Oncology, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2015–2022 94

Figure 67: Urologic Oncology, Global, Companies by Type, 2015–2022 95

Figure 68: Urologic Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Urological Cancer Specialization, 2015–2022 96

Figure 69: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancer, 2015–2022 97

Figure 70: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancers, Top Six Companies ($bn), 2015–2022 98

Figure 71: Urologic Oncology, Global, Licensing Deals, 2006–2016 100

Figure 72: Urologic Oncology, Global, Licensing Deals by Indication and Value, 2006–2016 101

Figure 73: Urologic Oncology, Global, Licensing Deals, 2006–2016 102

Figure 74: Urologic Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2016 103

Figure 75: Urologic Oncology, Global, Co-development Deals, 2006–2016 106

Figure 76: Urologic Oncology, Global, Co-development Deals by Indication and Value, 2006–2016 107

Figure 77: Urologic Oncology, Global, Co-development Deals, 2006–2016 108

Figure 78: Urologic Oncology, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2016 109

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards